Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-101 injection monotherapy or combination therapy in advanced malignant tumors (Phase I/II)
CTR20223293Phase 2Active
- Sponsor
- LaNova Medicines
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LM-101 in malignant solid tumor, lymphoma, sponsored by LaNova Medicines. Started Mar 2023; status: active.
02
Drugs
LM-101
03
Conditions
malignant solid tumorlymphoma
Beyond the preview
Go deeper on CTR20223293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223293.